Although cluster 2-related PPGLs show a very low metastatic risk, it is well worth mentioning that a phase 2 pediatric trial (MATCH, NCT04284774) evaluating tipifarnib, a farnesyl-transferase inhibitor that disrupts HRAS function, in patients with HRAS-mutant tumors, including pheochromocytomas, is currently recruiting and may provide important data for PPGL management (Table 2). The gene discussed is HRAS; the disease is pheochromocytoma.